| Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants |
21 |
| Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir |
17 |
| Antibody-mediated prevention and treatment of HIV-1 infection |
16 |
| Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs |
16 |
| Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers |
13 |
| Why was PERV not transmitted during preclinical and clinical xenotransplantation trials and after inoculation of animals? |
13 |
| The role of integration and clonal expansion in HIV infection: live long and prosper |
12 |
| Digital PCR as a tool to measure HIV persistence |
12 |
| Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir |
12 |
| Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1 |
11 |
| HIV evolution and diversity in ART-treated patients |
11 |
| What do we measure when we measure cell-associated HIV RNA |
11 |
| Nomenclature for endogenous retrovirus (ERV) loci |
10 |
| Hypericin-photodynamic therapy inhibits the growth of adult T-cell leukemia cells through induction of apoptosis and suppression of viral transcription |
10 |
| Engineering multi-specific antibodies against HIV-1 |
9 |
| HIV-1 cell-to-cell transmission and broadly neutralizing antibodies |
9 |
| Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? |
9 |
| Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? |
9 |
| The role of exosomal transport of viral agents in persistent HIV pathogenesis |
9 |
| HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth |
9 |
| Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes |
8 |
| CD8(+) T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication |
8 |
| Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies |
8 |
| Bovine leukemia virus proviral load is more strongly associated with bovine major histocompatibility complex class II DRB3 polymorphism than with DQA1 polymorphism in Holstein cow in Japan |
8 |
| Next-generation in situ hybridization approaches to define and quantify HIV and SIV reservoirs in tissue microenvironments |
8 |
| Reduction of inflammation and T cell activation after 6months of cART initiation during acute, but not in early chronic HIV-1 infection |
7 |
| Total HIV DNA: a global marker of HIV persistence |
7 |
| Comparative virology of HTLV-1 and HTLV-2 |
7 |
| Fused in sarcoma silences HIV gene transcription and maintains viral latency through suppressing AFF4 gene activation |
6 |
| RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency |
6 |
| Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency |
6 |
| An RNA-binding compound that stabilizes the HIV-1 gRNA packaging signal structure and specifically blocks HIV-1 RNA encapsidation |
6 |
| Potent suppression of HIV-1 cell attachment by Kudzu root extract |
6 |
| Host mRNA decay proteins influence HIV-1 replication and viral gene expression in primary monocyte-derived macrophages |
5 |
| Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design |
5 |
| Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies |
5 |
| CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4(+) T cells and hematopoietic stem/progenitor cells promotes HIV-1 resistance and CD4(+) T cell enrichment in humanized mice |
5 |
| Non-coding RNAs and retroviruses |
5 |
| Impact of LEDGIN treatment during virus production on residual HIV-1 transcription |
5 |
| Super-resolution fluorescence microscopy studies of human immunodeficiency virus |
5 |
| The expanding array of HIV broadly neutralizing antibodies |
5 |
| Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL |
5 |
| Promoter expression of HERV-K (HML-2) provirus-derived sequences is related to LTR sequence variation and polymorphic transcription factor binding sites |
4 |
| An insight to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) pathogenesis; evidence from high-throughput data integration and meta-analysis |
4 |
| Structural alteration of DNA induced by viral protein R of HIV-1 triggers the DNA damage response |
4 |
| Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient |
4 |
| Host SAMHD1 protein restricts endogenous reverse transcription of HIV-1 in nondividing macrophages |
4 |
| Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence |
4 |
| HIV latency reversing agents act through Tat post translational modifications |
4 |
| The HIV-1 accessory proteins Nef and Vpu downregulate total and cell surface CD28 in-CD4(+) T cells |
4 |
